Keywords: vivus, 2nd-qtr, loss, grows, qnexa, costs, higher
Vivus' 2nd-qtr loss grows 16% on Qnexa costs
Article | 13 August 2007
Higher operating expenses pushed California, USA-based drugmaker Vivus' second-quarter 2007 loss up 15.5% to $6.7 million, equivalent to $0.11 per share. The firm explained ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
